AHN Becomes 1st Health Care Organization in U.S. to Begin Phase 3 Clinical Trial for Ovarian Cancer Therapy
According to AHN, LGSOC is slow-growing and is less sensitive to standard chemotherapy.
According to AHN, LGSOC is slow-growing and is less sensitive to standard chemotherapy.